The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer

Clinical benefit from trastuzumab and other anti-human epidermal growth factor receptor-2 (HER2) therapies in patients with HER2-positive gastric cancer (GC) remains limited by primary or acquired resistance. We aimed to investigate the impact of concomitant molecular alterations to HER2 amplificati...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ji Yun, Hong, Mineui, Kim, Seung Tae, Park, Se Hoon, Kang, Won Ki, Kim, Kyoung-Mee, Lee, Jeeyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380124/
https://www.ncbi.nlm.nih.gov/pubmed/25786580
http://dx.doi.org/10.1038/srep09289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380124/
https://www.ncbi.nlm.nih.gov/pubmed/25786580
http://dx.doi.org/10.1038/srep09289

Ejemplares similares